Trials / Unknown
UnknownNCT02784093
Use of Gastrografin in the Management of Fecal Impaction in Patients With Severe Chronic Constipation
Use of Gastrografin in the Management of Fecal Impaction in Patients With Severe Chronic Constipation: A Double-blinded Randomized Controlled Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 83 (actual)
- Sponsor
- Jinling Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Fecal impaction (FI) is a common cause of lower gastrointestinal tract obstruction, and it is the result of chronic or severe constipation and most commonly found in the elderly population. Gastrografin is a water soluble contrast mediate that could act as an osmotic laxative. It has been shown to confer a therapeutic benefit in adhesive small bowel obstruction (SBO). The investigators speculate that gastrografin administrated orally may be more effective than enema in the treatment of fecal impaction induced intestinal obstruction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gastrografin | |
| PROCEDURE | enemas |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2017-05-01
- Completion
- 2017-12-01
- First posted
- 2016-05-26
- Last updated
- 2017-08-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02784093. Inclusion in this directory is not an endorsement.